homepage-top-section

The latest move follows a definitive agreement signed by the companies on 21 November this year. Merck stated that the tender offer will expire on 10 January next

Nitrase Therapeutics is deploying its NITROME platform for developing several therapies that target nitrases, a new enzymes class discovered by the company. The platform has created leads for

PreHevbrio has been approved for active immunisation against infection which is caused by all known subtypes of HBV in people aged 18 years and above. It is said

The designation will potentially facilitate the development and accelerate new therapies review for treating serious conditions which have unmet medical need. Moleculin noted that the company is now

Hummingbird Bioscience utilises its technologies to drug clinically-validated targets that have earlier been elusive. Its advanced programme, HMBD-001, is a HER3 antibody that targets an epitope on the

The multi-target, multi-year partnership will combine the clinical and commercial knowledge of Rallybio in rare diseases with AbCellera’s antibody discovery engine for identifying optimal clinical candidates and providing

Co-led by LYFE Capital and Novo Holdings, the financing round has also seen participation from existing investors OrbiMed Advisors and Versant Ventures. The latest funding will bring iECURE’s

The investigational new drug candidate reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species (RASP) that are elevated in ocular and systemic inflammatory disease. It represents a

The second-generation PDT photosensitiser drug, REM-001 has undergone late-stage clinical development in previous clinical trials. The REM-001 therapy includes three parts, a laser light source, a light delivery